Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 183
Filtrar
1.
Psychooncology ; 26(12): 2040-2047, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28264148

RESUMO

OBJECTIVE: To optimize personalized medicine for patients with hematological malignancies (HM), we find that knowledge on patient preferences with regard to information provision and shared decision-making (SDM) is of the utmost importance. The aim of this study was to investigate the SDM preference and the satisfaction with and need for information among newly diagnosed HM patients and their informal caregivers, in relation to sociodemographic and clinical factors, cognitive coping style, and health related quality of life. METHODS: Newly diagnosed patients and their caregivers were asked to complete the Hematology Information Needs Questionnaire, the Information Satisfaction Questionnaire, and the Threatening Medical Situations Inventory. Medical records were consulted to retrieve sociodemographic and clinical factors and comorbidity by means of the ACE-27. RESULTS: Questionnaires were completed by 138 patients and 95 caregivers. Shared decision-making was preferred by the majority of patients (75%) and caregivers (88%), especially patients treated with curative intent (OR = 2.7, P = .041), and patients (OR = 1.2, P < .001) and caregivers (OR = 1.2, P = .001) with a higher monitoring cognitive coping style (MCCS). Among patients, total need for information was related to MCCS (P = .012), and need for specific information was related to MCCS and several clinical factors. Importantly, dissatisfaction with the information they received was reported by a third of the patients and caregivers, especially patients who wanted SDM (χ2  = 7.3, P = .007), and patients with a higher MCCS (OR = 0.94, P = .038). CONCLUSION: The majority of HM patients want to be involved in SDM, but the received information is not sufficient. Patient-tailored information is urgently needed, to improve SDM.


Assuntos
Cuidadores/psicologia , Comunicação , Tomada de Decisões , Neoplasias Hematológicas/diagnóstico , Participação do Paciente , Satisfação Pessoal , Adaptação Psicológica , Adulto , Feminino , Neoplasias Hematológicas/psicologia , Neoplasias Hematológicas/terapia , Humanos , Masculino , Pessoa de Meia-Idade , Participação do Paciente/psicologia , Preferência do Paciente , Satisfação do Paciente , Relações Médico-Paciente , Qualidade de Vida , Encaminhamento e Consulta , Inquéritos e Questionários
2.
Artigo em Inglês | MEDLINE | ID: mdl-26840911

RESUMO

Patients with haematological malignancies undergoing autologous stem cell transplantation face a life-threatening illness and stressful treatment. Although many patients report problems, relatively few patients report a need for additional professional care after treatment. We aimed to gain insight into the factors underlying this discrepancy by exploring patients' needs and help-seeking behaviour in relation to their experienced symptoms and problems. A qualitative research design following the grounded theory approach was used. Twenty patients, treated with autologous stem cell transplantation in the past 2 years, participated in an individual semi-structured interview. Factors contributing to patients' help-seeking behaviour were derived from our data and ordered in the following categories: (1) transition from symptoms to problems; (2) preference for dealing with problems themselves and with help from relatives; (3) problem categories and coping strategies; and (4) motives for (not) bringing in professional help. We concluded that the mere presence of a symptom does not lead to help-seeking behaviour: this relationship is modified by patients' personal goals, future perspective and phase of recovery. Patients seem to prefer to deal with problems without professional care. Patients' actual appeal for professional care depends on their coping strategies, social network and knowledge of available care.


Assuntos
Comportamento de Busca de Ajuda , Transplante de Células-Tronco Hematopoéticas , Linfoma/terapia , Mieloma Múltiplo/terapia , Adaptação Psicológica , Adulto , Idoso , Feminino , Teoria Fundamentada , Neoplasias Hematológicas/psicologia , Neoplasias Hematológicas/terapia , Humanos , Linfoma/psicologia , Masculino , Pessoa de Meia-Idade , Mieloma Múltiplo/psicologia , Pesquisa Qualitativa , Transplante de Células-Tronco , Estresse Psicológico/psicologia , Transplante Autólogo
3.
Acta Oncol ; 55(11): 1273-1280, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27560599

RESUMO

BACKGROUND: Systematic evaluation and validation of new prognostic and predictive markers, technologies and interventions for colorectal cancer (CRC) is crucial for optimizing patients' outcomes. With only 5-15% of patients participating in clinical trials, generalizability of results is poor. Moreover, current trials often lack the capacity for post-hoc subgroup analyses. For this purpose, a large observational cohort study, serving as a multiple trial and biobanking facility, was set up by the Dutch Colorectal Cancer Group (DCCG). METHODS/DESIGN: The Prospective Dutch ColoRectal Cancer cohort is a prospective multidisciplinary nationwide observational cohort study in the Netherlands (yearly CRC incidence of 15 500). All CRC patients (stage I-IV) are eligible for inclusion, and longitudinal clinical data are registered. Patients give separate consent for the collection of blood and tumor tissue, filling out questionnaires, and broad randomization for studies according to the innovative cohort multiple randomized controlled trial design (cmRCT), serving as an alternative study design for the classic RCT. Objectives of the study include: 1) systematically collected long-term clinical data, patient-reported outcomes and biomaterials from daily CRC practice; and 2) to facilitate future basic, translational and clinical research including interventional and cost-effectiveness studies for both national and international research groups with short inclusion periods, even for studies with stringent inclusion criteria. RESULTS: Seven months after initiation 650 patients have been enrolled, eight centers participate, 15 centers await IRB approval and nine embedded cohort- or cmRCT-designed studies are currently recruiting patients. CONCLUSION: This cohort provides a unique multidisciplinary data, biobank, and patient-reported outcomes collection initiative, serving as an infrastructure for various kinds of research aiming to improve treatment outcomes in CRC patients. This comprehensive design may serve as an example for other tumor types.


Assuntos
Bancos de Espécimes Biológicos , Neoplasias Colorretais/patologia , Estudos de Coortes , Neoplasias Colorretais/sangue , Humanos , Países Baixos , Seleção de Pacientes , Estudos Prospectivos , Distribuição Aleatória , Inquéritos e Questionários
4.
Ann Hematol ; 95(1): 105-114, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26420062

RESUMO

Psychological distress contributes to impaired quality of life in hematological cancer patients. Stepped care treatment, in which patients start with the least intensive treatment most likely to work and only receive more intensive interventions if needed, could improve distress. We aimed to evaluate the outcome of stepped care treatment on psychological distress and physical functioning in patients treated with autologous stem cell transplantation for hematological malignancies. In the present study, we performed a randomized clinical trial with two treatment arms: stepped care and care as usual. Baseline assessment and randomization occurred during pre-transplant hospitalization. Stepped care was initiated after 6 weeks, consisting of (1) watchful waiting, (2) Internet-based self-help intervention, and (3) face-to-face counseling/ psychopharmacological treatment/ referral. Follow-up measurements were conducted at 13, 30, and 42 weeks after transplantation. Stepped care (n = 47) and care as usual (n = 48) were comparable on baseline characteristics. The uptake of the intervention was low: 24 patients started with step 1, 23 with step 2, and none with step 3. Percentages of distressed patients ranged from 4.1 to 9.7 %. Ten percent of patients received external psychological or psychiatric care. No statistically significant differences were found between stepped care and care as usual on psychological distress or physical functioning in intention to treat analyses, nor in per protocol analyses. The stepped care program was not effective in decreasing psychological distress. The low intervention uptake, probably related to the low levels of psychological distress, offers an explanation for this outcome. Future research should take into account patients' specific care needs. Netherlands Trial Registry identifier: NTR1770.


Assuntos
Neoplasias Hematológicas/psicologia , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Qualidade de Vida/psicologia , Estresse Psicológico/psicologia , Estresse Psicológico/terapia , Adulto , Feminino , Neoplasias Hematológicas/diagnóstico , Transplante de Células-Tronco Hematopoéticas/tendências , Humanos , Masculino , Pessoa de Meia-Idade , Estresse Psicológico/diagnóstico , Transplante Autólogo/tendências , Resultado do Tratamento
5.
Leukemia ; 30(1): 24-31, 2016 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-26183645

RESUMO

Large, comprehensive population-based studies in acute myeloid leukemia (AML) are scarce. We conducted a nationwide population-based study on treatment, trial participation and survival among all adult patients diagnosed with AML (n=12,032) and acute promyelocytic leukemia (APL; n=585) in the Netherlands between 1989-2012. Patients were categorized into four periods and four age groups (18-40, 41-60, 61-70 and >70 years). The application of allogeneic stem cell transplantation increased over time among AML patients up to age 70 years. For APL patients, the use of chemotherapy increased across all age groups. When a clinical trial was open for accrual in the Netherlands, the inclusion rates were 68%, 57%, 30% and 12% for AML patients in the four age groups, respectively (data for APL unavailable). Relative survival improved over time among AML (up to age 70 years) and APL patients. In the period 2007-2012, 5-year relative survival rates were 54%, 38%, 14% and 2% for AML patients and 84%, 75%, 54% and 37% for APL patients in the four age groups, respectively. As survival remained poor for older AML patients over the last two decades, clinical trials and active participation in those trials, are warranted that explore innovative treatment strategies for this elderly population.


Assuntos
Leucemia Mieloide Aguda/terapia , Participação do Paciente , Adolescente , Adulto , Idoso , Ensaios Clínicos como Assunto , Feminino , Transplante de Células-Tronco Hematopoéticas , Humanos , Leucemia Mieloide Aguda/mortalidade , Masculino , Pessoa de Meia-Idade , Países Baixos , Fatores de Tempo , Tretinoína/uso terapêutico , Adulto Jovem
7.
Qual Life Res ; 24(12): 2895-906, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26205768

RESUMO

PURPOSE: To describe the health-related quality of life (HRQoL) of an unselected population of patients with chronic lymphocytic leukaemia (CLL) including untreated patients. METHODS: HRQoL was measured by the EORTC QLQ-C30 including the CLL16 module, EQ-5D, and VAS in an observational study over multiple years. All HRQoL measurements per patient were connected and analysed using area under the curve analysis over the entire study duration. The total patient group was compared with the general population, and three groups of CLL patients were described separately, i.e. patients without any active treatment ("watch and wait"), chlorambucil treatment only, and patients with other treatment(s). RESULTS: HRQoL in the total group of CLL patients was compromised when compared with age- and gender-matched norm scores of the general population. CLL patients scored statistically worse on the VAS and utility score of the EQ-5D, all functioning scales of the EORTC QLQ-C30, and the symptoms of fatigue, dyspnoea, sleeping disturbance, appetite loss, and financial difficulties. In untreated patients, the HRQoL was slightly reduced. In all treatment stages, HRQoL was compromised considerably. Patients treated with chlorambucil only scored worse on the EORTC QLQ-C30 than patients who were treated with other treatments with regard to emotional functioning, cognitive functioning, bruises, uncomfortable stomach, and apathy. CONCLUSIONS: CLL patients differ most from the general population on role functioning, fatigue, concerns about future health, and having not enough energy. Once treatment is indicated, HRQoL becomes considerably compromised. This applies to all treatments, including chlorambucil, which is considered to be a mild treatment.


Assuntos
Nível de Saúde , Leucemia Linfocítica Crônica de Células B/psicologia , Qualidade de Vida , Adulto , Idoso , Clorambucila/efeitos adversos , Clorambucila/uso terapêutico , Dispneia/psicologia , Fadiga/psicologia , Feminino , Humanos , Leucemia Linfocítica Crônica de Células B/tratamento farmacológico , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Países Baixos , Transtornos do Sono-Vigília/psicologia , Inquéritos e Questionários
8.
Neth J Med ; 72(4): 235-41, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24829184

RESUMO

BACKGROUND: To investigate whether equal access to bortezomib has been achieved under the Dutch policy regulations that guarantee equal access to expensive inpatient drugs. METHODS: We investigated accessibility to bortezomib treatment at national and regional levels by (i) conducting interviews with stakeholders in the Dutch healthcare system to explore prescription barriers and (ii) tabulating sales data from 2004-2009 and trial participation rates. RESULTS: Interviews revealed awareness of the high treatment costs, although prescription barriers were not encountered. National use of bortezomib increased slowly (treating 2% of patients in 2004 to 17% in 2009), indicating a long adjustment period. Furthermore, use remains below the rate estimated by the professional association of haematologists (27%). Regional differences were found for both daily practice use (e.g. ranging from 13-27% in 2009) and clinical trial participation (e.g. ranging from 1-12% in 2006). CONCLUSION: Our results were somewhat conflicting: interviews did not reveal any prescription barriers, but quantitative methods showed regional differences, signs of underutilisation, and access inequality. Investigating use and accessibility, based on data triangulation, provides valuable feedback which can enhance evidence-based decision making for both physicians and policymakers. This could improve appropriate and efficient use and ensure equal access to expensive drugs.


Assuntos
Antineoplásicos/uso terapêutico , Ácidos Borônicos/uso terapêutico , Prescrições de Medicamentos/estatística & dados numéricos , Acessibilidade aos Serviços de Saúde , Padrões de Prática Médica , Pirazinas/uso terapêutico , Antineoplásicos/economia , Ácidos Borônicos/economia , Bortezomib , Ensaios Clínicos como Assunto , Custos de Medicamentos , Política de Saúde , Humanos , Entrevistas como Assunto , Países Baixos , Pirazinas/economia
9.
Bone Marrow Transplant ; 49(2): 292-8, 2014 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-24096825

RESUMO

Hematological malignancies and treatment with hematopoietic SCT are known to affect patients' quality of life. The problem profile and care needs of this patient group need clarification, however. This study aimed to assess distress, problems and care needs after allo- or auto-SCT, and to identify risk factors for distress, problems or care needs. In this cross-sectional study, patients treated with allo-SCT or auto-SCT for hematological malignancies completed the Distress Thermometer and Problem List. Three patient groups were created: 0-1, 1-2.5 and 2.5-5.5 years after transplantation. After allo-SCT, distress and the number of problems tended to be lower with longer follow-up. After auto-SCT, distress was highest at 1-2.5 year(s). Patients mainly reported physical problems, followed by cognitive-emotional and practical problems. A minority reported care needs. Risk factors for distress as well as problems after allo-SCT included younger age, shorter time after transplantation and GVHD. A risk factor for distress as well as problems after auto-SCT was the presence of comorbid diseases. Up to 5 years after auto-SCT or allo-SCT, patients continue to experience distress and problems. Judged by prevalence, physical problems are first priority in supportive care, followed by cognitive-emotional and practical problems.


Assuntos
Transplante de Células-Tronco Hematopoéticas/psicologia , Condicionamento Pré-Transplante/psicologia , Estudos Transversais , Feminino , Transplante de Células-Tronco Hematopoéticas/métodos , Humanos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Fatores de Risco , Condicionamento Pré-Transplante/métodos , Resultado do Tratamento
10.
Leuk Res ; 38(1): 84-90, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-24268350

RESUMO

We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) received ≥1 treatment lines during an average follow-up time of 6.4 years. The average total costs per patient were €41,417 (€539 per month). The costs varied considerably between treatment groups and between treatment lines. Although patients were treated with expensive chemo(immuno-)therapy, the main cost driver was inpatient days for other reasons than administration of chemo(immuno-)therapy.


Assuntos
Testes Diagnósticos de Rotina/economia , Tratamento Farmacológico/economia , Leucemia Linfocítica Crônica de Células B/diagnóstico , Leucemia Linfocítica Crônica de Células B/terapia , Transplante de Células-Tronco/economia , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise Custo-Benefício , Custos e Análise de Custo , Testes Diagnósticos de Rotina/métodos , Tratamento Farmacológico/métodos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos , Transplante de Células-Tronco/métodos
12.
J Clin Pharm Ther ; 38(1): 41-7, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23126374

RESUMO

WHAT IS KNOWN AND OBJECTIVE: High costs of novel agents increasingly put pressure on limited healthcare budgets. Demonstration of their real-world costs and cost-effectiveness is often required for reimbursement. However, few published economic evaluations of novel agents for multiple myeloma exist. Moreover, existing cost analyses were heavily based on conventionally treated patients. We investigated real-world health care costs of relapsed/refractory multiple myeloma in Dutch daily practice. METHODS: A retrospective medical chart review was conducted for 139 patients treated between January 2001 and May 2009. Total monthly costs attributable to each cost component were described across all regimens and for bortezomib-, thalidomide- and lenalidomide-based treatment regimens. RESULTS: Mean monthly total costs (€3,981) varied depending on the sequence of therapy (range: €442-€31,318). Significant cost drivers across all regimens included costs of therapy and hospital admissions. The acquisition costs for novel agents in particular accounted for 32% of mean total monthly costs. Prognostic factors associated with increased mean total monthly costs in multivariate regression analysis included low platelet counts (P = 0·01) and worsening performance status (P < 0·001). Mean total monthly costs of bortezomib- and lenalidomide-based regimens were significantly higher than those for thalidomide-based regimens in second, third and fourth treatment line. WHAT IS NEW AND CONCLUSIONS: Real-world costs during treatment of relapsed/refractory multiple myeloma vary greatly. Cost drivers include hospital admissions and acquisition costs of novel agents. Costs also vary by prognostic factors and treatment-related resource use. Future studies assessing the costs of combination therapy consisting of two or more novel agents are encouraged.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/economia , Custos de Medicamentos , Custos de Cuidados de Saúde , Mieloma Múltiplo/economia , Adolescente , Adulto , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Ácidos Borônicos/administração & dosagem , Bortezomib , Ensaios Clínicos Fase III como Assunto , Hospitalização/economia , Hospitalização/estatística & dados numéricos , Humanos , Lenalidomida , Pessoa de Meia-Idade , Mieloma Múltiplo/tratamento farmacológico , Mieloma Múltiplo/patologia , Análise Multivariada , Países Baixos , Prognóstico , Pirazinas/administração & dosagem , Recidiva , Análise de Regressão , Estudos Retrospectivos , Talidomida/administração & dosagem , Talidomida/análogos & derivados , Adulto Jovem
14.
Tijdschr Psychiatr ; 54(11): 921-5, 2012.
Artigo em Holandês | MEDLINE | ID: mdl-23138618

RESUMO

BACKGROUND: In the field of haemato-oncology the staging of disease began in the 1960s with the mapping of the extent of a disease in order to create opportunities for effective local treatment. This led to the characterisation of cancer cells with the help of various techniques ranging from microscopy to the profiling of gene expression. AIM: To provide an overview of staging and profiling in haematology. METHOD: A description is given of the relevant methods and techniques and of the way in which these procedures are organised in the Netherlands. RESULTS: In haematology it is essential to characterise an illness during diagnosis and during treatment. Slowly but surely protocols for estimating the severity of the patient's disease and patient's quality of life are being introduced. In the Netherlands the Dutch-Belgian Study Group for haemato-oncology for adults HOVON foundation) has been actively engaged for 25 years in integrating into one structure and one quality system the developments in disease profiling and the simultaneous improvements in treatment. CONCLUSION: In the treatment of patients with a haematological malignancy it has become normal practice to characterise both the diseased cell and the extent of the illness during diagnosis and in the course of treatment. Improvements in characterisation and in treatment run parallel to each other and influence each other continuously. The HOVON foundation keeps a record of the results of each patient.


Assuntos
Neoplasias Hematológicas/classificação , Neoplasias Hematológicas/diagnóstico , Oncologia/métodos , Qualidade de Vida , Neoplasias Hematológicas/patologia , Neoplasias Hematológicas/psicologia , Humanos , Estadiamento de Neoplasias , Índice de Gravidade de Doença , Resultado do Tratamento
15.
Ann Hematol ; 91(12): 1945-52, 2012 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-22864761

RESUMO

Haematopoietic stem cell transplantation (SCT) is an expensive lifesaving procedure, which is increasingly performed in patients with haematological diseases. Developments in the protocol for SCT have resulted in cost estimates that require updating. We aimed to calculate actual costs for SCT and to identify major cost drivers by means of a daily practice cost study. We randomly selected 191 patients, treated at three university hospitals, who underwent an autologous (auto) SCT or allogeneic (allo) SCT in 2007, 2008 or 2009. Allo-SCT included sibling donors, matched unrelated donors (MUD) and umbilical cord blood (UCB). Resource use was collected from the hospital registration systems and medical files. The total costs included selection and harvesting of stem cells, transplantation and 1-year follow-up. The average costs per patient were 45,670 € for auto-SCT and 101,919 € for sibling allo-SCT. The costs of transplantations from unrelated donors were much higher: 171,478 € for allo-SCT-MUD and 254,689 € for allo-SCT-UCB. Hospital inpatient days together with laboratory and other activities were the main cost drivers across all types of SCT. Besides, donor search costs were a large cost component in allo-SCT-sib (18 %) and allo-SCT-MUD (12 %). Real-world costs were above routine reimbursement and appropriate financing is necessary to guarantee the continuation of SCT. The costs calculated in this study provide reliable up-to-date input for cost-effectiveness studies and budget revision.


Assuntos
Custos de Cuidados de Saúde , Transplante de Células-Tronco Hematopoéticas/economia , Reembolso de Seguro de Saúde , Adulto , Idoso , Transplante de Células-Tronco de Sangue do Cordão Umbilical/economia , Custos e Análise de Custo , Registros Eletrônicos de Saúde , Feminino , Seguimentos , Hospitais Universitários , Humanos , Laboratórios Hospitalares/economia , Tempo de Internação , Masculino , Pessoa de Meia-Idade , Países Baixos , Transplante Autólogo , Transplante Homólogo , Adulto Jovem
16.
Bone Marrow Transplant ; 47(6): 757-69, 2012 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-21725373

RESUMO

Identifying factors that predict health-related quality of life (QOL) following hematopoietic SCT, is important in estimating patients' abilities to adjust to the consequences of their disease and treatment. As the studies that have been published on this subject are scattered, the present study aimed to systematically review prognostic factors for health-related QOL after auto- and allo-SCT in hematological malignancies. A systematic, computerized search in Medline, EMBASE, PsycINFO and the Cochrane Library was conducted from 2002 to June 2010. The methodological quality of the studies was assessed using an adaptation of Hayden's criteria list. Qualitative data synthesis was performed to determine the strength of the scientific evidence. In all, 35 studies fulfilled the selection criteria. Strong-moderate evidence was found for GVHD, conditioning regimen, being female, younger age, receiving less social support and pre-transplant psychological distress as predictors of various aspects of health-related QOL following hematopoietic SCT. The results of this review may help transplant teams in selecting patients at risk for experiencing a diminished health-related QOL following hematopoietic SCT. Follow-up treatment can be provided in order to promote QOL.


Assuntos
Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Qualidade de Vida , Fatores Etários , Feminino , Neoplasias Hematológicas/psicologia , Humanos , MEDLINE , Masculino , Fatores de Risco , Fatores Sexuais , Transplante Autólogo , Transplante Homólogo
17.
Ann Oncol ; 23(1): 171-182, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21464157

RESUMO

BACKGROUND: We studied progress in the fight against non-Hodgkin's lymphoma (NHL) in the Netherlands by describing the changes in incidence, treatment, relative survival, and mortality during 1989-2007. PATIENTS AND METHODS: We included all adult patients with NHL [i.e. all mature B-, T-, and natural killer (NK) cell neoplasms, with the exception of plasma cell neoplasms], newly diagnosed in the period 1989-2007 and recorded in the Netherlands Cancer Registry (n=55 069). Regular mortality data were derived from Statistics Netherlands. Follow-up was completed up to 1 January 2009. Annual percentages of change in incidence, mortality, and relative survival were calculated. RESULTS: The incidence of indolent B-cell and T- and NK-cell neoplasms rose significantly (estimated annual percentage change=1.2% and 1.3%, respectively); incidence of aggressive B-cell neoplasms remained stable. Mortality due to NHL remained stable between 1989 and 2003, and has decreased since 2003. Five-year relative survival rates rose from 67% to 75%, and from 43% to 52%, respectively, for indolent and aggressive mature B-cell neoplasms, but 5-year survival remained stable at 48% for T- and NK-cell neoplasms. CONCLUSIONS: In the Netherlands, incidence of indolent mature B-cell and mature T- and NK-cell neoplasms has increased since 1989 but remained stable for aggressive neoplasms. Survival increased for all mature B-cell neoplasms, preceding a declining mortality and increased prevalence of NHL (17 597 on 1 January 2008).


Assuntos
Linfoma não Hodgkin/epidemiologia , Distribuição por Idade , Idoso , Feminino , Humanos , Incidência , Linfoma não Hodgkin/patologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Países Baixos/epidemiologia , Prevalência , Sistema de Registros , Taxa de Sobrevida
18.
Bone Marrow Transplant ; 46(6): 840-6, 2011 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20818442

RESUMO

Autologous hematopoietic SCT (auto-SCT) has been effective therapy for refractory disease, in both malignancies and severe autoimmune diseases. It seems feasible and safe for refractory celiac disease (RCD) type II, although long-term results have not been evaluated yet. With current therapies, progression into enteropathy-associated T-cell lymphoma (EATL) occurs in 60-80% patients, with a high mortality rate. Therefore, it is important to evaluate new treatment strategies. Between March 2004 and February 2010, 18 RCD II patients were evaluated for auto-SCT preceded by conditioning with fludarabine and melphalan, as a consequence of unresponsiveness to cladribine therapy. Adverse events, survival rate, EATL development and change in clinical, histological and immunological course were monitored. Thirteen patients were transplanted successfully and followed up for >2 years, 4-year survival rate was 66%. Only one patient died because of transplant-related complications. The majority of patients showed an impressive clinical improvement and five a complete histological remission. In five patients, auto-SCT could not be performed; they all died with a median survival of 5.5 months. EATL was observed in one transplanted patient, only after 4 years of follow-up. Auto-SCT after conditioning with high-dose chemotherapy in RCD II patients unresponsive to cladribine therapy is feasible and seems promising.


Assuntos
Doença Celíaca/terapia , Cladribina/uso terapêutico , Transplante de Células-Tronco Hematopoéticas/métodos , Terapia de Salvação/métodos , Adulto , Idoso , Antineoplásicos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Condicionamento Pré-Transplante , Transplante Autólogo , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...